6 recruiting, 2 active not recruiting, 1 completed, 1 unknown. 7 Phase 2, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Recruiting 4, Active not recruiting 2, Completed 1 |
| Not applicable | 1 | Recruiting 1 |
Follow Adrenal Cortical Carcinoma: new trials by email Literature Review of Adrenal Cortical Carcinoma trials Research Report on Adrenal Cortical Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Cemiplimab as Maintenance Treatment for Advanced Adrenocortical Cancer Cemiplimab - Adrenal Cortical Carcinoma | Phase 2 | Recruiting | Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia | 31 | 2025-09-18 | 2025-10-06 |
| Characterization of the Strasbourg Cohort of Patients With Adrenal Cortex Carcinoma Adrenal Cortical Carcinoma | Recruiting | University Hospital, Strasbourg, France | 60 | 2025-06-10 | 2026-01-13 | |
| Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical Carcinoma Camrelizumab, Apatinib, mitotane - Adrenal Cortical Carcinoma, Adrenal Cortical Cancer | Phase 2 | Recruiting | West China Hospital | 28 | 2025-03-15 | 2025-06-03 |
| Cabozantinib in Combination With Pembrolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer Pembrolizumab, Biospecimen Collection, Cabozantinib S-malate - Locally Advanced Adrenal Cortex Carcinoma, Adrenal Cortical Carcinoma | Phase 2 | Recruiting | Emory University | 21 | 2025-01-15 | 2026-02-18 |
| Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001) individualized mRNA neoantigen vaccine (mRNA-0523-L001) - Adrenal Cortical Carcinoma, Medullary Thyroid Cancer | Not applicable | Recruiting | Shanghai Jiao Tong University School of Medicine | 21 | 2024-01-13 | 2026-04-09 |
| PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma Dexamethasone, PDS01ADC, Intera 3000 Hepatic Artery Infusion Pump (HAIP) - Metastatic Colorectal Cancer (Mcrc), Intrahepatic Cholangiocarcinoma (Icc) | Phase 2 | Recruiting | National Cancer Institute (NCI) | 70 | 2022-10-24 | 2026-10-16 |
| Development of Clinical Evidence for Optimal Management of Adrenal Diseases Based on Real-World Data Adrenal Tumor, Primary Aldosteronism | Unknown | Seoul National University Hospital | 8200 | 2022-05-10 | 2024-03-04 | |
| Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors Cabozantinib, Cabozantinib S-malate, Pharmacological Study - Adrenal Cortical Carcinoma, Alveolar Soft Part Sarcoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 109 | 2017-05-18 | 2026-08-28 |
| Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Biospecimen Collection, Computed Tomography, Echocardiography Test - Acinar Cell Carcinoma, Adenoid Cystic Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 798 | 2017-01-30 | 2026-06-17 |
| A Study of Combination Chemotherapy and Surgical Resection in the Treatment of Adrenocortical Carcinoma: Continuous Infusion Doxorubicin, Vincristine and Etoposide With Daily Mitotane Before and After Surgical Resection doxorubicin, vincristine, and etoposide with mitotane - Adrenal Cortical Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 42 | 1993-08-01 | 2008-03-04 |
Adrenocortical Carcinoma (10) · Adrenal Gland Neoplasms (3) · Adrenal Cortex Neoplasms (2) · Bile Duct Neoplasms (2) · Carcinoma, Medullary (2) · Cholangiocarcinoma (2) · Pheochromocytoma (2) · Adenocarcinoma, Bronchiolo-Alveolar (1) · Adenocarcinoma, Mucinous (1) · Adenoma, Islet Cell (1) · Carcinoma, Acinar Cell (1) · Carcinoma, Adenoid Cystic (1) · Carcinoma, Basal Cell (1) · Carcinoma, Endometrioid (1) · Carcinoma, Giant Cell (1)
Adenocarcinoma (10) · Adrenal Cortex Diseases (10) · Adrenal Gland Diseases (10) · Carcinoma (10) · Endocrine Gland Neoplasms (10) · Endocrine System Diseases (10) · Neoplasms (10) · Neoplasms by Histologic Type (10) · Neoplasms by Site (10) · Neoplasms, Glandular and Epithelial (10) · Adrenal Cortex Neoplasms (8) · Adrenal Gland Neoplasms (7) · Digestive System Diseases (4) · Digestive System Neoplasms (4) · Neoplasms, Germ Cell and Embryonal (4)
Magnetic Resonance Spectroscopy (2) · Mitotane (2) · Specimen Handling (2) · cabozantinib (2) · CTLA-4 Antigen (1) · Dexamethasone (1) · Doxorubicin (1) · Etoposide (1) · Floxuridine (1) · Ipilimumab (1) · Nivolumab (1) · Vincristine (1) · apatinib (1) · camrelizumab (1) · cemiplimab (1)
National Cancer Institute (NCI) (4) · Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (1) · Emory University (1) · Seoul National University Hospital (1) · Shanghai Jiao Tong University School of Medicine (1) · University Hospital, Strasbourg, France (1) · West China Hospital (1)
United States (5) · China (2) · France (1) · Guam (1) · Italy (1) · South Korea (1)
Alfredo Berruti, Prof, MD (1) · Jonathan M Hernandez, M.D. (1) · Jung Hee Kim, MD, PhD (1) · Sandip P Patel (1) · Shahid S. Ahmed, MBBS (1) · Srivandana Akshintala (1)
PMID 31401903, PMID 31969335, PMID 33362722, PMID 33882143, PMID 34380663, PMID 34716198, PMID 38243705, PMID 38358334, PMID 38989414, PMID 39067873, PMID 39343510, PMID 39417692, PMID 39583952, PMID 39856213, PMID 40402690, PMID 40588371, PMID 40812353, PMID 41672597, PMID 41892875, PMID 41995270, PMID 42365236, PMID 42499790
P30CA138292 (1), U10CA180886 (1), U10CA180888 (1)